BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24905725)

  • 1. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study.
    Hirata T; Izumi G; Takamura M; Saito A; Nakazawa A; Harada M; Hirota Y; Koga K; Fujii T; Osuga Y
    Gynecol Endocrinol; 2014 Oct; 30(10):726-9. PubMed ID: 24905725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term dienogest administration in patients with symptomatic adenomyosis.
    Neriishi K; Hirata T; Fukuda S; Izumi G; Nakazawa A; Yamamoto N; Harada M; Hirota Y; Koga K; Wada-Hiraike O; Fujii T; Osuga Y
    J Obstet Gynaecol Res; 2018 Aug; 44(8):1439-1444. PubMed ID: 29845696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.
    Osuga Y; Watanabe M; Hagino A
    J Obstet Gynaecol Res; 2017 Sep; 43(9):1441-1448. PubMed ID: 28737239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis.
    Ota K; Takahashi T; Shiraishi S; Mizunuma H
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1787-1792. PubMed ID: 29998482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.
    Fawzy M; Mesbah Y
    Arch Gynecol Obstet; 2015 Dec; 292(6):1267-71. PubMed ID: 25990480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis.
    Xue J; Li L; Li F; Li N; Li T; Li C
    J Reprod Immunol; 2020 Feb; 137():103079. PubMed ID: 31927399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.
    Grandi G; Xholli A; Napolitano A; Palma F; Cagnacci A
    Reprod Sci; 2015 May; 22(5):626-32. PubMed ID: 25394646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis.
    Takeuchi A; Koga K; Miyashita M; Makabe T; Sue F; Harada M; Hirata T; Hirota Y; Fujii T; Osuga Y
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():157-161. PubMed ID: 27865118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study.
    Strowitzki T; Faustmann T; Gerlinger C; Seitz C
    Eur J Obstet Gynecol Reprod Biol; 2010 Aug; 151(2):193-8. PubMed ID: 20444534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
    Hassanin AI; Youssef AA; Yousef AM; Ali MK
    Int J Gynaecol Obstet; 2021 Aug; 154(2):263-269. PubMed ID: 33454995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Behavior of parameters of liver metabolism in intermediate-term use of the gestagen dienogest in the treatment of endometriosis].
    Köhler G; Lembke S; Brachmann K; Foth D; Happke S
    Zentralbl Gynakol; 1989; 111(12):807-10. PubMed ID: 2763750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of endometriosis with dienogest].
    Köhler G; Göretzlehner G; Amon I
    Zentralbl Gynakol; 1987; 109(12):795-801. PubMed ID: 3630463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
    Osuga Y; Fujimoto-Okabe H; Hagino A
    Fertil Steril; 2017 Oct; 108(4):673-678. PubMed ID: 28911934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest.
    Nagata C; Yanagida S; Okamoto A; Morikawa A; Sugimoto K; Okamoto S; Ochiai K; Tanaka T
    J Obstet Gynaecol Res; 2012 Apr; 38(4):639-44. PubMed ID: 22413833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
    Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
    J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
    Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
    Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis.
    Schindler AE; Christensen B; Henkel A; Oettel M; Moore C
    Gynecol Endocrinol; 2006 Jan; 22(1):9-17. PubMed ID: 16522528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
    Miao J; Lu J; Tang J; Lu P
    Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
    Matsushima T; Akira S; Yoneyama K; Takeshita T
    Gynecol Endocrinol; 2020 Jun; 36(6):521-524. PubMed ID: 31661345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dienogest over 53 weeks for the treatment of endometriosis.
    Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.